Benzinga · Jul 17, 2026
Tvardi Therapeutics Increases At-The-Market Offering Program To $9.69M In Shares
- Sec Filing
TV
NASDAQ · TVRD
Tvardi Therapeutics, Inc.
Healthcare · Biotechnology
$0.84
Down-$0.10 (-10.41%)
Updated Oct 27, 2026, 10:06 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 42.12M
- P/E ratio
- -3.02
- Dividend yield
- 0.00%
- 52-week range
- $0.92 – $5.69
- Volume
- 139.58K
- Avg. volume
- 308.7K
Price performance · TVRD
TVRD price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 26, 2026
TVRD closed at $0.84 after 21 trading sessions, down 36.68% for the selected period.
- Last close
- $0.84
- Period change
- -36.68%
- Period low
- $0.84
- Period high
- $1.33
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 26, 2026 | $0.94 | $0.97 | $0.842 | $0.8421 | 139.58K |
| Oct 23, 2026 | $1.0702 | $1.0702 | $0.9201 | $0.94 | 108.87K |
| Oct 22, 2026 | $1.01 | $1.0499 | $0.9722 | $0.9722 | 55.41K |
| Oct 21, 2026 | $1.02 | $1.09 | $1.00 | $1.02 | 137.1K |
| Oct 20, 2026 | $1.03 | $1.0764 | $0.97 | $0.992 | 195.19K |
| Oct 19, 2026 | $1.01 | $1.0279 | $0.9687 | $0.97 | 201.34K |
| Oct 16, 2026 | $1.05 | $1.0686 | $1.00 | $1.01 | 91.84K |
| Oct 15, 2026 | $1.03 | $1.07 | $1.00 | $1.07 | 94.58K |
| Oct 14, 2026 | $1.01 | $1.03 | $0.99 | $1.00 | 75.72K |
| Oct 13, 2026 | $1.06 | $1.0601 | $1.0116 | $1.04 | 73.45K |
| Oct 12, 2026 | $1.02 | $1.08 | $0.97 | $1.06 | 248.22K |
| Oct 9, 2026 | $1.09 | $1.09 | $1.02 | $1.03 | 130.29K |
| Oct 8, 2026 | $1.10 | $1.10 | $1.04 | $1.08 | 160.04K |
| Oct 7, 2026 | $1.08 | $1.11 | $1.04 | $1.10 | 136.47K |
| Oct 6, 2026 | $1.15 | $1.18 | $1.07 | $1.08 | 148.3K |
| Oct 5, 2026 | $1.17 | $1.17 | $1.12 | $1.14 | 148.92K |
| Oct 2, 2026 | $1.25 | $1.277 | $1.13 | $1.15 | 313.81K |
| Oct 1, 2026 | $1.25 | $1.31 | $1.21 | $1.24 | 332.65K |
| Sep 30, 2026 | $1.29 | $1.32 | $1.20 | $1.25 | 232.69K |
| Sep 29, 2026 | $1.32 | $1.42 | $1.26 | $1.28 | 254.08K |
| Sep 28, 2026 | $1.27 | $1.3699 | $1.19 | $1.33 | 351.44K |
Latest TVRD news
The latest Smart Investors Daily articles mentioning TVRD.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TVRD research
Overview
Company profile and research snapshot.
Company profile
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $4.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 20, 2026 | Chardan Capital | Buy | — |
| Jul 30, 2026 | BTIG | Buy | — |
| Jul 8, 2026 | Raymond James | Outperform | — |
| Jul 7, 2026 | BTIG | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Jul 9, 2026
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences (NASDAQ:FBRX) stock rose
Benzinga · Jul 9, 2026
Why Is Tvardi Therapeutics Stock Falling Thursday?
Tvardi Therapeutics stock dips premarket as investors take profits after positive Phase 1 data for Tvardi's STAT3 prodrug TTI-109.
Benzinga · Jul 9, 2026
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) stock increased by 134.0% to $7.44 during Thursday's pre-market session. The company's market cap stands at $2.5 million. Alnylam Pharmaceuticals (NASDAQ:ALNY) stock
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
